Sussex Research Laboratories Inc. scientists presented data on the Company’s promising research & development program on carbohydrate-based anti-aging actives. Sussex Research Laboratories Inc. scientists presented the latest results on the Company’s anti-aging carbohydrate-based molecules at the International Federation of Societies for Cosmetic Chemists Congress in Paris, France. The poster, entitled “Post Translationally Modified Cosmeceutical Actives,” was extremely well received.
About Sussex Research Laboratories Inc.: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research Laboratories Inc. excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research Laboratories Inc. excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
SHARE THIS ARTICLE ON:
Get product updates and announcements from Sussex Research in your inbox at no charge.
Sussex Research Laboratories Inc. to Exhibit at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics
May 4, 2022
Sussex Research Laboratories Inc. to Exhibit at The American Peptide Symposium 2022 - "Peptide Science at the Summit"
April 26, 2022
Sussex Research Laboratories Inc. / Queen’s University collaboration receives support to develop novel small molecule therapies for COVID-19
May 21, 2020
Sussex Research Laboratories Inc. / Queen’s University collaboration receives Collaborative Research and Development Grant (CRDPJ) to develop synthetic strategies toward Deuterium-labeled pharmaceutical compounds with improved efficacy.
August 22, 2018
Sussex Research Laboratories Inc. acquires Chemaphor Chemical Services from Avivagen
October 13, 2017